Nuclio News and MyNuclio combine industry journalism, professional networking and commercial intelligence to serve one of healthcare’s fastest-growing sectors
As billions of dollars flowinto radiopharmaceuticals, medical isotopes and precision oncology, a new mediacompany is betting that one of healthcare's fastest-growing industries needsmore than another publication—it needs its own commercial ecosystem.
Today, Nuclio announced thelaunch of Nuclio News, adigital business publication covering the global nuclear medicine economy,alongside MyNuclio, aprofessional networking platform designed exclusively for organizations andprofessionals across the nuclear medicine industry. Together, the platformsrepresent a new approach to vertical media, combining business journalism,industry networking and commercial intelligence into a single ecosystem builtfor a specialized healthcare market.
"For decades, thenuclear medicine industry has relied on fragmented information sources, tradeshows and personal relationships to stay connected," said BrianFitzgerald, founder and CEO of Nuclio. "We saw an opportunity to build thedigital infrastructure the industry has never had; a place where companies canfollow the market, professionals can build meaningful industry connections andthe commercial side of nuclear medicine becomes more transparent."
Unlike traditionalhealthcare publications that broadly cover life sciences or medical technology,Nuclio News focuses exclusively on the business of nuclear medicine. Itseditorial coverage spans radiopharmaceutical development, isotope production,manufacturing, molecular imaging, theranostics, hospital systems, nuclearpharmacies, artificial intelligence, investment, mergers and acquisitions,clinical development and the companies shaping the industry's future.
At the same time, MyNuclioextends beyond publishing by providing professionals and organizations with adedicated platform to build profiles, connect with peers, showcase expertise,claim company pages, post career opportunities and strengthen commercialrelationships across the global nuclear medicine community.
The launch reflects abroader shift occurring throughout business media, where specialized digitalplatforms are increasingly combining content, community and proprietary datarather than relying solely on traditional advertising models.
"Every major industryeventually develops digital infrastructure that helps people discover companies,build relationships and make better business decisions," Fitzgerald said."Financial markets have Bloomberg. Venture capital has PitchBook. Salesteams rely on ZoomInfo. Nuclear medicine has experienced extraordinaryscientific innovation over the past decade, but its commercial infrastructurehas largely remained disconnected. That's the problem we're setting out tosolve."
Nuclio's long-term visionextends beyond publishing. As organizations and professionals establishverified profiles and engage with industry content, the company plans to builda comprehensive commercial graph of the nuclear medicine economy—mappingcompanies, products, facilities, partnerships and market relationships tosupport future intelligence, recruiting and business development services.
Industry growth hasaccelerated dramatically in recent years as radiopharmaceuticals move intomainstream oncology, driving significant investment in isotope production,manufacturing capacity, imaging technologies and targeted therapies. Yet muchof the industry's commercial information remains fragmented across disconnecteddatabases, company websites, conferences and personal networks.
Nuclio believes thatcreating a unified digital platform for the sector can help improve market visibility,facilitate commercial connections and provide deeper insight into one ofhealthcare's fastest-evolving markets.
Nuclio News and MyNuclio arenow live and available globally.